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Influence of Age on Outcome From Thrombolysis in
Acute Stroke
A Controlled Comparison in Patients From the Virtual International
Stroke Trials Archive (VISTA)
Nishant Kumar Mishra, MBBS; Hans-Christoph Diener, MD, PhD;
Patrick D. Lyden, MD, FAHA, FAAN; Erich Bluhmki, PhD; Kennedy R. Lees, MD, FRCP; for the
VISTA Collaborators
Background and Purpose—Thrombolysis for acute ischemic stroke in patients aged 80 years is not approved in some
countries due to limited trial data in the very elderly. We compared outcomes between thrombolysed and
nonthrombolysed (control) patients from neuroprotection trials to assess any influence of age on response.
Method—Among patients with ischemic stroke of known age, pretreatment severity (baseline National Institutes of Health
Scale Score), and 90-day outcome (modified Rankin Scale score; National Institutes of Health Scale score), we
compared the distribution of modified Rankin score in thrombolysed patients with control subjects by Cochran-Mantel-
Haenszel test and then logistic regression after adjustment for age and baseline National Institutes of Health Scale score.
We examined patients 80 and 81 years separately and then each age decile.
Results—Rankin data were available for 5817 patients, 1585 thrombolysed and 4232 control subjects; 20.5% were aged 80
years (meanSD, 85.13.4 years). Baseline severity was higher among thrombolysed than control subjects (median National
Institutes of Health Scale score 14 versus 13, P0.05). The distribution of modified Rankin Scale scores was better among
thrombolysed patients (P0.0001; OR, 1.39; 95% CI, 1.26 to 1.54). The association occurred independently with similar
magnitude among young (P0.0001; OR, 1.42; 95% CI, 1.26 to 1.59) and elderly (P0.002; OR, 1.34; 95% CI, 1.05 to 1.70)
patients. ORs were consistent across all age deciles30 years; outcomes assessed by National Institutes of Health Scale score
gave supporting significant findings, and dichotomized modified Rankin Scale score outcomes were also consistent.
Conclusions—Outcome after thrombolysis for acute ischemic stroke was significantly better than in control subjects.
Despite the expected poorer outcomes among elderly compared with young patients that is independent of any treatment
effect, the association between thrombolysis treatment and improved outcome is maintained in the very elderly. Age
alone should not be a barrier to treatment. (Stroke. 2010;41:2840-2848.)
Key Words: elderly  outcome  thrombolysis
Thrombolysis for acute ischemic stroke has proven benefits,but randomized trial data in patients 80 years are limit-
ed.1–5 To date, the European Medicines Evaluation Agency has
not approved thrombolysis with alteplase among the very elder-
ly.4,6,7 Patients80 years represent approximately 30% of acute
stroke incidence.2,4,8,9 Many experienced centers treat the elderly
but others observe the terms of product approval.7,10,11
The National Institute of Neurological Disorders and
Stroke trial initially restricted enrollment to patients aged up
to 80 years.1 The age criterion was lifted after enrolling 188
patients in Part A of the trial, but only 42 very elderly patients
were enrolled.1 All European Cooperative Acute Stroke
Study (ECASS) trials applied an upper age limit of 80 years,5
and recent studies with desmoteplase also excluded the
elderly.12 The main reasons advanced for withholding treat-
ment from the elderly patients in clinical practice are fears
that advancing age is associated with poorer prognosis with
greater risk for hemorrhage and in-hospital mortality.13,14
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Conversely, a meta-analysis of pooled thrombolysis data
concluded that the risks of symptomatic intracerebral hemor-
rhage (ICH) did not increase among the elderly despite less
favorable outcomes.10 Less favorable outcomes are expected
to occur in the elderly, mostly due to comorbidity.4,15
The proportion of elderly is rising in our society.8 In the
United Kingdom alone, the population aged 80 years has
doubled since 1982.16 Effective treatments should not be
withheld from the elderly in the absence of compelling data
suggesting unacceptable risk or proven lack of benefit. We
hypothesized that clinical practice over the last decade would
have been sufficiently diverse to allow analysis of existing
rigorously collected clinical data17 to construct a comparison
of thrombolysis against matched control subjects with the
possibility of adjusting for any imbalance in severity. We
anticipated that use in the elderly would be sufficiently
frequent to assess the influence of age on any association of
stroke outcome with thrombolysis treatment.
Methods
Data Source and Patients
We collated the demographics, clinical data, and measures of
functional outcome from neuroprotection trials conducted in the
period 1998 to 2007 held within the Virtual International Stroke
Trials Archive (VISTA; www.vista.gla.ac.uk).17 All trials held nec-
essary review board and regulatory approvals, and patients consented
to participation; only anonymized data are held by VISTA. We
sought data from VISTA deriving from trials in which the investi-
gational neuroprotection agent was not vasoactive or interfered with
clotting or from placebo groups. We excluded any patient who had
cerebral hemorrhage or stroke of undetermined etiology. To avoid
dual publication, we excluded patients who may have been enrolled
in Safe Implementation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST)18 determining this from their country and date of
enrollment. Finally, we excluded patients lacking our chosen out-
come measure, 90-day modified Rankin Score (mRS), or secondary
outcome, 90-day National Institutes of Health Stroke Scale (NIHSS)
score. Patients who died within 90 days were given an mRS score of
6 and categorized separately for NIHSS analysis.
Statistical Analysis
We undertook a nonrandomized, adjusted comparison of outcomes
between patients who received recombinant tissue plasminogen
activator (rtPA) and patients who did not receive rtPA (henceforth
referred to as treated and control groups, respectively) among
patients who met the age criterion for the European alteplase
marketing authorization. We repeated the comparison among pa-
tients aged 81 years. We then examined the association of
thrombolysis treatment with outcome within each age decile to
illustrate the strength of evidence across the full age range. For each
contrast, we compared the overall distribution of all 7 categories of
Day 90 mRS scores of the 2 groups, that is, from 0 (asymptomatic)
through 5 (bedbound and completely dependent), to 6 (dead). The
European Medicines Evaluation Agency Points to Consider for
reporting trials allows use of the full range of the Rankin scores and
further suggests that this can be supported by a secondary analysis of
another outcome measure such as NIHSS.19 For analysis of our
supporting end point, NIHSS, we grouped adjacent scores into
categories: 0 (no measurable deficit), 1 to 4, 5 to 8, 9 to 12, 13 to 16,
17 to 20, 21 to 24, 25 (most severe neurological deficit), or dead.
The distribution of patients across these categories was then com-
pared between the groups as for mRS. To test for a significant
association of outcome distribution with thrombolysis exposure, we
used the Cochran-Mantel-Haenszel (CMH) statistic adjusting for
both age and baseline NIHSS as continuous variables.20,21 This
nonparametric approach avoids invoking an assumption of propor-
tional odds in which there should be a common OR across all cut
points on the ordinal outcome scale, and we consider that the CMH
test provides the most conservative estimate of statistical signifi-
cance. However, it does not express the extent of the association. For
this, we applied logistic regression analysis, also adjusted for age and
baseline NIHSS, to estimate the OR under the assumption of
proportional odds and its associated 95% CI.22 Stratification by
covariates in the CMH test is limited by the sample size and
precludes simultaneous adjustment for all possible variables. Hence,
we prospectively planned to adjust for age and baseline NIHSS and
to consider other variables only in exploratory analyses. Our choice
of baseline factors for adjustment was based on 2 influences.22 First,
age and baseline severity are the 2 most powerful prognostic factors
for stroke and are usually included in outcome distribution analy-
ses.23,24 Second, age and NIHSS data were available for our entire
sample, whereas other factors of potential interest were incomplete.
However, we also undertook a sensitivity analysis by considering the
combined effect of the variables that differed significantly at baseline.
For comparison with prior randomized trial and registry reports,
we also present dichotomized analyses of mRS based on favorable
outcome (mRS 0 to 1), independence (mRS 0 to 2), and survival;
these analyses were expressed as ORs adjusted for age and baseline
NIHSS, like for the primary and secondary end points.25 ORs in our
analysis express the common odds of an improved distribution of
outcome in association with alteplase treatment. CMH and logistic
regression analysis were undertaken using SAS 9.2 software and
other analyses by StatsDirect software. Reliable information on
symptomatic hemorrhage was not available because posttreatment
imaging was not routinely applied in neuroprotection trials to
patients who had not been treated with alteplase.
Results
Patient Sample
We collated data on 9665 patients of whom 5342 (59%) were
enrolled from non-European sites. To avoid dual publication
with SITS-MOST,18 we excluded 2789 patients (28%) enrolled
from European sites between 2002 and 2006 and 177 patients for
whom we lacked information on nationality. Complete data
were available for analysis of mRS in 5817 patients and on
NIHSS in 5715 (description of data available online, see sup-
plement; available at http://stroke.ahajournals.org).
All patients with stroke were treated as per institutional
practice and stroke guidelines acceptable at the point of trial
conduct. Monitoring for protocol compliance was undertaken on
behalf of sponsors for these trials. This implies that when
thrombolysis was administered, this was in accordance with
marketing authorization for the relevant country, that is, that
treatment started within 3 hours of stroke onset; however, the onset
to treatment delay is not recorded for thrombolysis in these trials.
Our data derived mainly from Northern American (60%),
European (16%), and Australasian (13%) centers.
Baseline characteristics are shown in the Table. Of the
5817 patients with mRS outcome data, 1585 (27.2%) re-
ceived thrombolysis. Baseline severity was higher by 1
NIHSS point among the younger patients who received
thrombolysis therapy compared with our control group;
among patients aged 80 years, severity was equal between
treated and control groups. The delay between stroke onset
and initiation of alteplase was not recorded, but the delay to
research enrollment and initiation of the investigational prod-
uct was shorter in the thrombolysis group than control
subjects irrespective of age (3.7 versus 5.1 hours, P0.0001).
Independently, baseline NIHSS accounted for 28% and age
for 9.7% of the variation in 90-day outcome by mRS (both
Mishra et al Influence of Age on Outcome in Stroke Thrombolysis 2841
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P0.0001) and were included in all models, together explain-
ing 33.5% of the variation.
Overall Outcome
Across our whole sample, the distribution of mRS scores was
better among thrombolysed patients (P0.0001; OR, 1.39;
CI, 1.26 to 1.54).
Outcomes Among Patients Aged <80 Years
Among the 4623 patients with 90-day mRS data, treatment
with thrombolysis was associated with a significantly more
favorable distribution of mRS scores (Figure 1; CMH
P0.0001; adjusted OR, 1.4; 95% CI, 1.3 to 1.6). The
unadjusted OR was 1.2 (95% CI, 1.1 to 1.4). Dichotomized
comparisons were also significant for independence (mRS 0
Table. Baseline Characteristics of the Patients
Thrombolysis Control P
Age, mean years (range)
All 71 (21–98) N1585 72 (21–101) N4232 0.05
Young age 80 67 (21–80) N1284 69 (21–80) N3339 0.05
Elderly age 80 84 (81–98) N301 84 (75–101) N893 0.58
Sex, male
All 880/1585 55.52% 2226/4232 52.6% 0.05
Young age 80 750/1284 58.4% 1874/3339 56.1% 0.16
Elderly age 80 130/301 34.9% 352/893 39.4% 0.25
Baseline NIHSS
All 14 (2–32) N1585 13 (2–37) N4232 0.05
Young age 80 13 (2–30) N1284 12 (2–32) N3339 0.05
Elderly age 80 15 (4–32) N301 15 (2–37) N893 0.70
Prior antiplatelets
All 429/1078 39.8% 446/1306 34.2% 0.05
Young age 80 323/881 (36.7%) 335/1049 31.9% 0.03
Elderly age 80 106/197 53.8% 111/257 43.2 0.02
Prior anticoagulation
All 67/1078 6.2% 198/1306 15.2% 0.05
Young age 80 49/881 5.6% 151/1049 14.4% 0.05
Elderly age 80 18/197 9.1% 47/257 18.3% 0.01
Previous stroke
All 319/1555 20.5% 1579/4076 38.7% 0.05
Young age 80 248/1255 19.8% 1178/3201 36.8% 0.05
Elderly age 80 71/300 23.7% 401/875 45.8% 0.05
Congestive heart failure
All 151/1262 12% 164/1409 11.6% 0.79
Young age 80 100/1019 9.8% 106/1136 9.3% 0.70
Elderly age 80 51/243 21% 58/273 21.3% 0.94
Diabetes mellitus
All 342/1548 22.1% 992/3991 24.9% 0.03
Young age 80 293/1250 23.4% 816/3136 26% 0.08
Elderly age 80 49/298 16.4% 176/855 20.6% 0.12
Hypertension
All 1030/1548 66.5% 2827/3991 70.8% 0.05
Young age 80 813/1250 65.04 2163/3136 69% 0.01
Elderly age 80 217/298 72.8% 664/855 77.7% 0.09
Atrial fibrillation
All 398/1548 25.7% 1274/3991 31.3% 0.05
Young age 80 268/1250 21.4% 807/3136 25.7% 0.05
Elderly age 80 130/298 43.6% 440/855 51.5% 0.02
Myocardial infarction
All 278/1548 18% 691/3991 17.3% 0.57
Young age 80 227/1250 18.2% 529/3136 16.9% 0.31
Elderly age 80 51/298 17.1% 162/855 19% 0.48
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to 2 versus 3 to 6; OR, 1.54; 95% CI, 1.33 to 1.79;
P0.0001); for favorable outcome (mRS 0 to 1 versus 2 to 6;
OR, 1.31; 95% CI, 1.12 to 1.53; P0.0008); and for survival
(OR, 1.44; 95% CI, 1.18 to 1.76; P0.0004).
The functional outcomes were supported by the secondary
end point (Figure 2). The spectrum of NIHSS scores at 90
days was significantly better among the thrombolysed pa-
tients than control subjects (CMH P0.0001; adjusted OR,
1.6; 95% CI, 1.4 to 1.8; n4537). The unadjusted comparison
yielded an OR of 1.3 (95% CI, 1.2 to 1.5).
Our sensitivity analysis, in which we adjusted for age,
baseline NIHSS, previous stroke, hypertension, and atrial
fibrillation, also yielded CMH P0.0001.
Outcomes Among Patients Aged >81 Years
Among the 1194 very elderly patients with 90-day mRS data,
treatment with thrombolysis was associated with a signifi-
cantly more favorable distribution of mRS scores (Figure 1;
CMH P0.002; adjusted OR, 1.34; 95% CI, 1.05 to 1.70).
The unadjusted OR was 1.26 (95% CI, 1.00 to 1.59; CMH
P0.05). The dichotomized comparison was significant for
independence (mRS 0 to 2; OR, 1.52; 95% CI, 1.06 to 2.17;
P0.022). For favorable outcome (mRS 0 to 1), the OR was
1.46 (95% CI, 0.97 to 2.20, P0.07); and for survival, the OR
was 1.20 (95% CI, 0.90 to 1.65; P0.20).
The functional outcomes were supported by the second-
ary end point (Figure 2). The spectrum of NIHSS scores at
90 days was significantly better among the thrombolysed
patients than control subjects (CMH P0.0004; adjusted
OR, 1.4; 95% CI, 1.1 to 1.8; n1178). The unadjusted
comparison yielded a similar estimate (OR, 1.4; 95% CI,
1.1 to 1.7).
Our sensitivity analysis, in which we adjusted for age,
baseline NIHSS, hypertension, previous stroke, and atrial
fibrillation, also yielded CMH P0.02.
Association of Thrombolysis With Outcome by
Age Decile
Both functional outcome (Figure 3) and neurological out-
come (Figure 4) were significantly better among thrombol-
ysed patients than control subjects within each decile of age
from 51 years to 90 years; and except among the small sample
of 21- to 30-year-old patients, point estimates for the adjusted
ORs were consistent across all age groups.
Discussion
Our analysis demonstrates that use of thrombolysis for acute
stroke is associated with better functional and neurological
outcomes, and probably lower mortality, in all adult patients
Figure 1. Diagram showing association of functional outcomes with use of rtPA in the younger patients (age 80 years) and elderly
patients (age 80 years) having acute ischemic stroke. Each box of the horizontal bar corresponds to the mRS category specified by
the color code. Upper horizontal bar belongs to control group of young and elderly patients and lower to the rtPA-treated patients in
each age group. Numbers in each box denote the percent of total patients belonging to a specific treatment category (rtPA or control)
and representing the mRS score corresponding to the box.
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who are treated irrespective of their age. It supports the
limited randomized trial data and places data on safety from
stroke registries in context.
Our data draw validity from 4 origins. First, the source
clinical trials of investigational medicinal products were
undertaken under strict controls on reporting of concomitant
treatments and outcomes, and on-site data verification
procedures were in place for each trial. Second, attitudes to
treatment of the very elderly vary among clinicians, some
European clinicians strictly following the European Med-
icines Evaluation Agency marketing authorization and
others in Europe and North America treating without
regard to age.26,27 Third, our estimates of control outcomes
correspond closely to those from the published randomized
controlled trials of thrombolysis,3,28 our estimates of out-
comes among our treated group aged 80 years corre-
spond closely to those of the randomized controlled trials
and of large case series such as SITS-MOST,18 our
estimate of outcomes in very elderly treated patients
corresponds closely to those of Safe Implementation of
Thrombolysis in Stroke–International Stroke Thromboly-
sis Register,29 and our estimate of treatment ORs in the
patients aged 80 years closely corresponds to treatment
effects demonstrated in the randomized controlled tri-
als.5,28 Furthermore, it would be more surprising if we had
found an influence of age on the association between
treatment and outcome, because there is no biological
reason to expect treatment failure according to age, and
there is evidence from other disease areas to support
independence of treatment effects on age or even of larger
absolute benefits among the elderly.4 We acknowledge that
dose-finding studies have not been undertaken in the very
elderly, however. Fourth, we chose as our primary end
point the mRS, which is the most prevalent outcome
measure in recent stroke trials30 and we followed an
approach to analysis that is described in the European
Medicines Evaluation Agency Points to Consider for
interpretation of clinical trials in acute stroke.19 There,
comparison of the distribution of the full range of the mRS
is proposed as acceptable with supporting evidence from a
secondary end point such as NIHSS: both are positive and
give similar estimates of benefit in our comparison.31
Furthermore, although the less powerful dichotomized
analyses are not all significant among the very elderly,
they each give point estimates for magnitude of association
that correspond to the estimates derived in the young and
from the full mRS or NIHSS distributions.
Ironically, it shows that young patients 30 years may
suffer harm from alteplase. This we believe could be due to
other stroke mechanisms that play a role in younger age
Figure 2. Diagram showing association of neurological outcomes with use of rtPA in the younger patients (age 80 years) and elderly
patients (age 80 years) having acute ischemic stroke. Each box of the horizontal box corresponds to the mRS category specified by
the color code. Upper horizontal bar belongs to control group of young and elderly patients and lower to the rtPA-treated patients in
each age group. Numbers in each box denote the percent of total patients belonging to a specific treatment category (rtPA or control)
and representing the mRS score corresponding to the box.
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groups that are not related with thrombus that are sensitive to
alteplase.
There are also limitations to our study that must be
considered. Our data are based on a nonrandomized compar-
ison, and there is a high potential for selection bias for
thrombolytic treatment. Although many of the usual descrip-
tors of baseline prognosis are reasonably matched between
our groups, and although we have adjusted our analyses for
the most important of these, age and baseline severity,24
which together account for 33.5% of the variation in out-
come, we could not adjust for every factor. Atrial fibrillation,
use of warfarin, and prior diabetes were all less prevalent
among our treated group. However, the magnitude of these
differences was small, the absolute differences were equal for
young versus very elderly, and our sensitivity analyses with
adjustment for these additional factors also yielded signifi-
cantly positive findings. This implies that although our
estimate of the association of treatment with outcome may be
imprecise, our estimates of trends in this measure across the
age range are robust. Some of the patients in our study
received an investigational neuroprotective agent and we
must consider that these could interact with thrombolysis;
however, each contributing trial has already tested for, and
excluded, a significant interaction. VISTA data handling
procedures preclude further testing for effects of the original
investigational agent or identification of source trials.
We do not know the delay between stroke onset and
treatment initiation in our thrombolysis group, but the time of
baseline NIHSS assessment is earlier in the thrombolysed
than nonthrombolysed patients. Presentation delay is associ-
ated with outcome, but this is mediated through earlier
presentation of more severe stroke, a factor that favored our
control group in the young only. Last is the possibility of
systematic bias in other aspects of care and thus outcome
between centers that used thrombolysis routinely versus those
that did not or that restricted use in the elderly. We cannot
counter criticism on this point, except to indicate that the
contributing trials sought to minimize such effects through
site selection, training of investigators, and monitoring of
care and of outcomes; and to point again to the correspon-
dence of outcomes in each of our treatment groups with those
from randomized controlled trials and registry data.
Trials and registries of thrombolysis generally report 3
outcomes: functional attainment, mortality, and symptomatic
or serious ICH.15,18,29 We lack data on the last of these,
because patients who are not treated with thrombolysis
generally do not undergo follow-up cerebral imaging for
routine detection of hemorrhagic transformation. Fortunately,
information on this aspect can be inferred from other sources:
the rate of serious or symptomatic bleeding is very low
among patients who do not receive thrombolysis, approxi-
mately 1%,5,28,32–34 and registry data such as Safe Implemen-
tation of Thrombolysis in Stroke (SITS) inform us on the rate
among treated patients and have found no significant increase
in the very elderly compared with the young.35 A more
Figure 3. Forest plot showing association of functional outcomes with improved outcomes in patients who received thrombolytic ther-
apy. Patients are shown stratified by age groups and corresponding forest plot, OR, CI, CMH P, and sample size are marked.
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important response on the issue of serious bleeding comes
from our use of the full mRS distribution as our outcome
measure. Bleeding is relevant only if it affects eventual
functional outcome. Dichotomization of mRS outcomes into
0 to 1 versus 2 to 6 or 0 to 2 versus 3 to 6 could conceal
harmful results of serious bleeding reflected by higher pro-
portions of severely disabled patients within the unfavorable
outcome group (for example, more mRS 5 among patients
with mRS 3 to 5). Our data and analysis approach exclude this
possibility; even if hemorrhage were more common in the very
elderly than young, which has been discounted,35,36 this does not
translate into poorer functional outcomes after adjustment for
age and stroke severity.
Data on stroke outcomes associated with thrombolysis use
in the elderly come from 3 other sources. A meta-analysis of
cohort studies by Ringleb and colleagues in 2007 found that
the elderly experienced similar rates of symptomatic hemor-
rhage as the young (6.1% versus 5.1%) but higher mortality
(32% versus 14%) with fewer attaining favorable outcome by
90 days (mRS 0 to 1: 26% versus 41%).36 However, within 1
of the largest studies in this analysis, the baseline severity of
stroke was much higher in elderly than young patients
(NIHSS 16 versus 13.9, respectively).37 Outcomes of very
elderly patients described by the SITS registry reinforce these
findings; stroke severity was higher in the 643 elderly versus
6749 younger patients, NIHSS 15 versus 13. Symptomatic
ICH was no more common in the very elderly (2.0% [95% CI,
1.1 to 3.5] versus 1.5% [1.2 to 1.8]), but 90-day mortality was
higher (31% [27 to 36] versus 15% [14 to 16]); and
independence (mRS 0 to 2) was achieved less frequently
(30% [26 to 34] versus 52% [51 to 53]).35 Interpretation of
these uncontrolled registry findings is compromised by the
known influence of age and stroke severity on outcome in the
absence of thrombolysis treatment. Only 164 patients aged
80 years were included among the large randomized trials
combined.1,5,28,34,38,39 The elderly group was again more
severely affected at baseline than the younger patients, but
there was also a severity imbalance among the elderly that
favored the control subjects. A pooled analysis of these data
in the elderly (0 to 4.5 hours subgroup: N137 of 2199)
estimated ORs for independence (mRS 0 to 2 at Day 90) and
mortality under alteplase versus placebo of 1.09 and 1.28,
respectively, based on unadjusted data. However, after ad-
justment for the demonstrable imbalance in baseline NIHSS,
the ORs, respectively, improved to 1.77 and 0.96 (Boehringer
Ingelheim, data on file, see online supplement). The sample
size was small and none of these outcomes reached statistical
significance. Thus, our present findings are entirely consis-
tent with the randomized trial data not only in terms of the
estimated extent of benefit from treatment, but also with
regard to the influence of baseline severity on the interpreta-
tion of outcomes.
Treatment allocation in our study was not randomized, and
a randomized controlled trial would more conclusively in-
Figure 4. Forest plot showing association of neurological outcomes with improved outcomes in patients who received thrombolytic
therapy. Patients are shown stratified by age groups and corresponding forest plot, OR, CI, CMH P, and sample size are marked.
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form the influence of rtPA on outcomes among elderly. Two
trials currently aim to examine this topic.40,41 There is an
Italian trial that has so far enrolled approximately 10% of the
planned 600 patients over a 2-year period.40 The International
Stroke Trial-3 aims to examine outcomes among all patients
who receive thrombolytic therapy and has prescribed no
upper age limit.41,42 Over 12 years, the trial has enrolled
approximately 2000 patients from the originally planned
6000.42 Approximately one third of these patients are very
elderly and being treated within the time window of inter-
est.2,41,42 Although our analysis is not a randomized con-
trolled trial, it is the only current source of evidence to
support the registry and randomized controlled trial data that
are currently available.2,10,37,43–45
In summary, outcome among patients treated with
thrombolysis as standard of care within clinical research trials
is more favorable than among patients who are not offered
thrombolysis, and this apparent advantage to patients who are
treated extends to patients aged 81 years. We not only fail
to find evidence to support the present restriction of the
European marketing authorization for alteplase use in the
elderly; we find positive evidence that alteplase is beneficial
among patients aged 81 to 90 years and that this is likely to
extend even to patients aged 91 to 100 years. Our data support
and extend the extensive uncontrolled data on outcomes from
registries and the limited randomized controlled trial data.
Age is not a relevant factor when considering whether to use
alteplase for acute stroke.
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SUPPLEMENTAL MATERIAL 
 
 
The following document contains supplemental material published online 
with “Influence of age on outcome from thrombolysis in acute stroke: a 
controlled comparison in patients from the Virtual International Stroke 
Trials Archive (VISTA)” by Mishra NK et al.  This material comprise a flow 
chart showing description of VISTA data used in the main analysis of 
paper ( page 2 and3) and a supplementary appendix “Overview of 
efficacy and safety in the randomized controlled clinical trials” (page 4 
to 13). The appendix is based on data extracted and text edited by KR 
Lees from a regulatory submission document prepared by Dr T Machnig, 
based on analyses conducted by Dr E Bluhmki. 
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Figure:  A flow diagram describing selection of data from VISTA 
neuroprotection trials (1998-2007) for the analyses reported.
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Appendix: Overview of efficacy and safety in the randomized controlled 
clinical trials. 
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Overview of efficacy and safety in the randomized controlled clinical trials  
There has been no formal clinical trial programme for very elderly patients aged ≥80 
years. So far, in randomized trials of alteplase for acute stroke treatment, few patients 
aged ≥80 years were included and randomized. The majority of these patients derive from 
part 2 of the NINDS trial, in which age >80 years was not an exclusion criterion. In 
contrast, an age of ≥80 years was an exclusion criterion in NINDS part 1, ECASS II, 
ECASS III, ATLANTIS A and ATLANTIS B.(1-4) Nevertheless, some patients aged ≥80 
years were still included in these trials.  
 
 
Methods 
 
To gain insight into the efficacy and safety of treatment with alteplase under randomized 
controlled trial (RCT) conditions in this group, the available data on patients aged ≥80 
years from trials using 0.9 mg/kg of alteplase were pooled. Overall, 164 very elderly 
patients (age ≥80 years) were enrolled and treated in the six randomized trials. Of those 
very elderly patients, 137 were treated in the 0–4.5 hour time window. The NINDS trial 
contributed most of the patients (22 from part 1 and 56 from part 2), with 15 from 
ECASS-II, 34 from ECASS-III and 2 and 8 from ATLANTIS parts A and B respectively. 
(1-4)
 
 
The main efficacy outcome measures in the pooled analysis were excellent outcome 
(mRS 0 or 1) and favourable outcome (mRS 0–2) at day 90. The main safety endpoints 
analyzed in the pooled data set of the very elderly were incidence of any intracranial 
haemorrhage (ICH), the incidence of symptomatic ICH (sICH) as defined by the SITS-
MOST definition,(5) and mortality.  
For both safety and efficacy, odds ratios (OR) given in the paragraphs that follow are 
adjusted for NIHSS at baseline and are also presented as unadjusted ORs.  
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Due to imbalances between treatment arms regarding the severity of stroke at baseline in 
this cohort (figure A-1), two subgroups were defined according to their NIHSS score at 
baseline:  
• 48 very elderly patients with severe stroke at baseline (NIHSS ≥20)  
• 89 very elderly patients (NIHSS <20), excluding patients with severe stroke.  
These subgroups were viewed alongside comparable subgroups from a cohort of younger 
patients (<80 years old) pooled from the same RCTs. 
 
Results 
Baseline demographics  
Very elderly patient cohort – overall  
Amongst the patients at and above (≥) 80 years of age, most were marginally over 80: 
median 81 years, range 80-101. A striking imbalance of the mean /median NIHSS at 
baseline between the very elderly cohort and the younger cohort was apparent. Very 
elderly patients receiving alteplase had a clinically relevant 5 point higher median NIHSS 
at baseline than younger patients (Table A-1). Within the very elderly cohort there was a 
3 point difference in the median NIHSS to the detriment of the alteplase group. Post hoc 
categorisation of the stroke severity at baseline by three NIHSS severity categories (0–9, 
10–19 and ≥20) demonstrated that this imbalance in baseline stroke severity in the very 
elderly group was driven mainly by a disproportionately higher number of alteplase-
treated patients (n=31) compared with placebo-treated patients (n=17) in the most severe 
category of baseline stroke (NIHSS score ≥20):   19 vs 20; 26 vs 24; 31 vs 17 
respectively.  
Other risk factors known to be associated with poor outcomes after stroke, independent of 
treatment, were also more prevalent within the very elderly compared to the younger 
patients, including hypertension, atrial fibrillation and the use of concomitant aspirin at 
baseline. A history of smoking was less common among the very elderly and the 
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proportion of females was increased. However, within the very elderly group, prognostic 
factors such as diabetes, atrial fibrillation, prior stroke and aspirin use were well matched. 
Subgroup of very elderly patients excluding those with severe stroke  
The median NIHSS score in this subgroup of very elderly patients excluding those with 
severe stroke at baseline did not differ from that in the subgroup of younger patients 
(median score 11.0). The mean and median NIHSS scores in the very elderly subgroup 
were also balanced between treatment arms (alteplase group: median 11.0; mean 11.2; 
placebo group: median 10.5; mean 11.0). With respect to other risk factors (e.g. 
hypertension, atrial fibrillation and prior aspirin) the findings in this subgroup mirrored 
those in the overall cohort of the very elderly patients.  
Subgroup of very elderly patient with severe stroke  
In this subgroup of the very elderly with severe stroke at baseline (NIHSS ≥20) the 
median NIHSS score was 1.5 points higher compared with their younger counterparts. 
The median NIHSS scores in the alteplase-treated arm (23.0) versus the placebo-treated 
arm (25.0) were balanced in this subgroup of the very elderly.  
Regarding other risk factors, such as hypertension, atrial fibrillation and prior aspirin use, 
the findings in this subgroup of patients with severe stroke at baseline reflected the 
findings in the overall patient cohort of the very elderly patients.  
Functional neurological outcome at day 90  
Very elderly patient cohort – overall (n=137)  
The efficacy results for the 0–4.5 hour cohort of very elderly patients (n=137) are shown 
in tables A-1 and A-2. 
 
In the very elderly patient group there was no significant clinical benefit with alteplase 
treatment before adjustment for baseline imbalance in severity. In terms of excellent 
outcome (mRS 0 - 1) the absolute benefit was 1.4% in favour of alteplase over placebo; 
in terms of favourable outcome (mRS 0–2) the absolute benefit was 2.1% in favour of 
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alteplase over placebo. After adjustment for baseline NIHSS the point estimates for 
excellent outcome (OR 1.72; 95 % CI 0.67–4.41) and favourable outcome (OR 1.77; 95 
% CI 0.73–4.25) were consistent with a higher chance for good outcome in the very 
elderly treated with alteplase compared with placebo, but the confidence intervals were 
not sufficiently narrow to exclude the possibility of harm with treatment.  
The treatment effect observed in the very elderly cohort was also not as pronounced as 
that observed in the younger cohort. In the patients aged <80 years old a significant 
treatment effect was observed in terms of excellent outcome (absolute benefit with 
alteplase 9.7%; OR 1.43; 95 % CI 1.18–1.75) and favourable outcome (absolute benefit 
with alteplase 8.6%; OR 1.35; 95% CI 1.11–1.64).  
Subgroup of very elderly patients excluding those with severe stroke  
In this subgroup excluding patients with severe stroke, a clinically meaningful absolute 
difference of 8.1% in favour of alteplase was observed for the endpoint mRS 0-1 and of 
10.1% for the endpoint mRS 0–2. However, the confidence intervals for the adjusted ORs 
were wide for both excellent (mRS 0 or 1: OR 1.63; 95% CI 0.63–4.21) and favourable 
outcome (mRS 0–2: OR 1.87; 95% CI 0.71–4.91).  
Subgroup of very elderly patients with severe stroke  
In the small subgroup of very elderly patients with severe stroke at baseline (48 patients) 
the functional outcome at 3 months was very poor. None of the patients in the placebo 
arm achieved excellent outcome (mRS 0 or 1), though one patient in the alteplase arm 
did. One patient in the placebo arm and 3 patients in the alteplase arm had favourable 
outcome (mRS 0–2) at day 90.  
Safety outcomes  
Very elderly patient cohort – overall  
In the very elderly patient cohort mortality at 90 days was more than twice the level seen 
in the younger patient cohort, both in the alteplase arm and the placebo arm. Among the 
very elderly there was an absolute excess of mortality of 4.7% in the alteplase arm 
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compared with the placebo arm (27.6% versus 23.0%), whereas the level of mortality 
among patients aged <80 years was comparable between treatment arms (10.2% vs. 
11.5%, respectively). The adjusted OR for mortality in the younger patients (<80 years) 
was 0.92 (95% CI 0.69–1.23) and for the patients ≥80 years 0.96 (95% CI 0.36–2.59).  
The incidence of any ICH was increased for both the very elderly and the younger 
patients in the alteplase arm compared with the placebo arm. This increased risk in the 
alteplase arm was more pronounced in patients aged ≥80 years (OR 4.01; 95% CI 1.76–
9.13) than in patients aged <80 years (OR 1.44; 95% CI 1.17–1.77). Similar findings 
were made for sICH (as per SITS-MOST definition(5)), with a higher OR for sICH in the 
alteplase arm in the very elderly cohort than in the younger cohort.  
Subgroup of very elderly patients excluding those with severe stroke  
In this subgroup of the very elderly excluding those with severe stroke the rate of 
mortality at 90 days was comparable between treatment arms. Overall mortality in the 
alteplase arm was 8.9% versus 11.4% in the placebo arm. The adjusted OR for mortality 
was 0.61 (95% CI 0.13–2.88) in the patients aged ≥80 years and 0.88 (95% CI 0.61–1.27) 
in patients <80 years. These point estimates again indicate that alteplase treatment in the 
very elderly may not necessarily be associated with excess mortality.  
The incidence of any ICH was increased for both the very elderly and the younger 
patients in the alteplase arm compared with the placebo arm. Again, this increased risk in 
the alteplase arm was more pronounced in the very elderly (OR 4.82; 95% CI 1.55–
14.94) compared with younger patients (OR 1.53; 95% CI 1.20–1.95). Similar 
observations were made for sICH (as per SITS-MOST definition(5)), with a higher OR for 
sICH in the alteplase arm in patients aged ≥80 years compared with patients aged <80 
years.  
Subgroup of very elderly patients with severe stroke  
In the subgroup of very elderly patients with severe stroke at baseline, mortality at 90 
days was very high, regardless of treatment arm (54.8% with alteplase versus 52.9% with 
placebo). Overall mortality at 90 days was more than twice as high in the very elderly 
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compared with their younger counterparts, and was observed equally in the placebo arm 
(52.9% vs 23.3%, respectively) and the alteplase arm (54.8% vs 25.6%, respectively). 
The adjusted OR for mortality was 1.36 (95% CI 0.37–4.98) for patients aged ≥80 years 
and 0.99 (95% CI 0.61–1.62) for patients aged <80 years. Again the point estimates 
indicate that alteplase treatment in the very elderly may not necessarily be associated 
with excess mortality.  
The incidence of any ICH was increased for both the very elderly and the younger 
patients in the alteplase arm compared with the placebo arm. Again, this increased risk in 
the alteplase arm was more pronounced in the very elderly patients (OR 3.03; 95% CI 
0.88–10.47) compared with the younger patients (OR 1.37; 95% CI 0.91–2.06). Similar 
observations were again made for sICH (as per SITS-MOST definition(5)), with a higher 
OR for sICH in the alteplase arm in the very elderly than in the younger age group. 
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Conclusions  
Only 137 very elderly patients aged ≥80 years were included in the 0–4.5 hour time window 
in all of the RCTs of alteplase used at the standard dose of 0.9 mg/kg bodyweight. This small 
number of patients provides low power to assess treatment effects. Although there appeared 
to be a minimal absolute benefit with alteplase treatment in the total cohort of the very 
elderly, this contrasted with the absolute benefit of 9.7% for excellent outcome observed in 
the cohort of patients younger than 80 years. Looking at the baseline data it became obvious 
that the most important prognostic baseline parameter, namely stroke severity, was heavily 
skewed to the disadvantage of the alteplase arm. Excluding patients with severe stroke at 
baseline (NIHSS ≥20) left a subgroup of 89 very elderly patients in whom the NIHSS scores 
at baseline were balanced between treatment arms. In this subgroup of very elderly patients 
with a baseline NIHSS score of <20, the absolute treatment benefit of alteplase over placebo 
for excellent outcome was found to be in the same range (8.1%) as that in younger patients 
with a baseline NIHSS score of <20 (8.8%). Differences between the treatment arms were not 
statistically significant. Except in a subgroup of patients with very advanced age and severe 
stroke in whom outcomes are poor, adverse safety outcomes show no excess amongst 
alteplase treated patients in the very elderly group. 
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Table A-1 
Baseline demography and 90-day outcome.  
 
  
Younger <= 80 years Very elderly >= 80 years 
  
Alteplase Placebo alteplase placebo 
N  1021 1041 76 61 
Age Mean 64.6 64.9 82.4 82.5 
Median, range 67 (20-79) 67 (23-79) 81 (80-98) 81 (80-101) 
Diabetes N, % 196 (19%) 184 (18%) 14 (18%) 12 (20%) 
Atrial 
fibrillation  
N, % 158 (16%) 171 (16%) 34 (45%) 25 (41%) 
Prior stroke N, % 132 (13%) 155 (15%) 10 (13%) 8 (13%) 
Prior aspirin 
or other 
antiplatelet 
N, % 317 (31%) 315 (30%) 35 (46%) 24 (39%) 
Baseline 
NIHSS 
Mean 13.0 13.7 16.5 15.0 
Median, range 12.0 (1-46) 13.0 (1-37) 17.0 (4-32)  14.0 (2-34) 
      
mRS 0-1 N, % 470 (46%) 378 (36%) 21 (28%) 16 (26%) 
mRS 0-2 N, % 592 (58%) 514 (49%) 29 (38%) 22 (36%) 
Mortality N, % 104 (10%) 120 (12%) 21 (28%) 14 (23%) 
Post 
treatment ICH 
N, % 295 (29%) 245 (24%) 39 (51%) 13 (21%) 
Post 
treatment 
sICH 
N, % 25 (2.4%) 5 (0.5%) 5 (6.6%) 0 (0.0%) 

ICH: intracerebral haemorrhage 
SICH: symptomatic intracerebral haemorrhage, as defined for the Safe Implementation of 
Thrombolysis in Stroke Monitoring Study (SITS-MOST).( 5) 
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 Younger <= 80 years Very elderly >= 80 years 
90-day 
outcomes 
 OR 95% CI P OR 95% CI p 
mRS 0-1 Unadjusted 1.50 1.25-1.78 <0.0001 1.07 0.50-2.30 0.85 
 Adjusted* 1.43 1.18-1.75 0.0003 1.72 0.67-4.41 0.26 
        
mRS 0-2 Unadjusted 1.41 1.19-1.68 <0.0001 1.09 0.54-2.20 0.80 
 Adjusted* 1.35 1.11-1.64 0.003 1.77 0.73-4.25 0.20 
        
Mortality Unadjusted 0.87 0.66-1.15 0.33 1.28 0.59-2.80 0.53 
 Adjusted* 0.92 0.69-1.23 0.57 0.96 0.36-2.59 0.94 
Any ICH  1.32 1.08-1.61 0.006 3.89 1.82-8.32 0.0005 
  1.44 1.17-1.77 0.0005 4.01 1.76-9.13 0.0009 
SICH Unadjusted 5.20 1.98-13.6 0.0008 8.52@ 0.46-
159.0 
0.15 
 Adjusted* 5.24 2.00-13.8 0.0008 #   
 
*Adjusted for NIHSS at baseline 
@imputation of incidence of 0.5 in case of no event 
#an adjusted analysis was not possible due to the limited incidence of events 
ICH: intracerebral haemorrhage 
SICH: symptomatic intracerebral haemorrhage, as defined for the Safe Implementation of 
Thrombolysis in Stroke Monitoring Study (SITS-MOST)(5) 
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Correction 
 
The article entitled “Influence of Age on Outcome From Thrombolysis in Acute Stroke: 
A Controlled Comparison in Patients From the Virtual International Stroke Trials 
Archive (VISTA)” by Mishra et al that published online ahead of print on October 28, 
2010 included data that needs to be updated in Figures 1 and 2 and the Table. The 
alterations are as follows: “<81” should be replaced by “≤80.” This will be corrected for 
the print and final online versions. The authors regret this error. 
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